Bleomycin Sulfate

[{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bleomycin Sulphate","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"University of Sydney","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bleomycin Sulphate","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"University of Sydney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sydney \/ Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California","highestDevelopmentStatusID":"10","companyTruncated":"University of Sydney \/ Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California"}]